Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety follow-up of inhaled liposomal ciclosporin A after lung transplantation
2011-004304-38Phase 3Terminated
- Sponsor
- PARI Pharma
- Start
- Nov 2011
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label trial of cyclosporine in Bronchiolitis Obliterans Syndrome (BOS) and Lung allograft rejection (LAR) (2 arms), sponsored by PARI Pharma. Primary endpoint: Long-term safety of inhaled liposomal ciclosporin A. Started Nov 2011; status: terminated.
02
Drugs
cyclosporine
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)Lung allograft rejection (LAR)
Beyond the preview
Go deeper on 2011-004304-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004304-38.